![]() The OMERACT logo used since 2012 | |
![]() Group photo of attendees at the inaugural OMERACT conference held in Maastricht, The Netherlands, from April 29 to May 3, 1992 | |
Formerly | Outcome Measures in Rheumatoid Arthritis Clinical Trials (1992–1996) |
---|---|
Industry | Medical Research |
Founded | April 29, 1992 in Ottawa, Ontario, Canada |
Founders |
|
Key people |
|
Website | www.omeract.org |
Outcome Measures in Rheumatology (OMERACT) is an international initiative aimed at improving outcome measurement in rheumatology. Established in 1992, OMERACT organizes biennial consensus conferences to develop and refine core sets of measures for rheumatologic conditions, with an emphasis on data-driven recommendations.... [1]
OMERACT was initiated by Dr. Peter Tugwell and Dr. Maarten Boers, who observed discrepancies in outcome measures between European and North American rheumatoid arthritis clinical trials. The first conference was held in Maastricht, the Netherlands, in 1992. The initiative was originally chaired by 4 member executive committee consisting of Dr. Maarten Boers, Dr. Peter Brooks, Dr. Peter Tugwell, and Dr. Vibeke Strand. [2]
OMERACT's mission is to improve endpoint outcome measurement through an iterative, data-driven process. The key activities include:
OMERACT has achieved consensus on Core Outcome Sets for conditions such as rheumatoid arthritis, osteoarthritis, and osteoporosis. [5] The measures endorsed by OMERACT are widely adopted in clinical trials and systematic reviews, contributing to standardization in the field. [2] OMERACT’s methodology has been emulated in other medical fields and international collaborations [6] [7] [8] [9] [10] [11] [12] [13]
OMERACT operates as a registered not-for-profit organization in Canada [14]
Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, including skin, eyes, lungs, heart, nerves, and blood. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.
Rheumatology is a branch of medicine devoted to the diagnosis and management of disorders whose common feature is inflammation in the bones, muscles, joints, and internal organs. Rheumatology covers more than 100 different complex diseases, collectively known as rheumatic diseases, which includes many forms of arthritis as well as lupus and Sjögren's syndrome. Doctors who have undergone formal training in rheumatology are called rheumatologists.
Methotrexate, formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease. It can be given by mouth or by injection.
Rheumatism or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue. Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and "non-articular rheumatism", also known as "regional pain syndrome" or "soft tissue rheumatism". There is a close overlap between the term soft tissue disorder and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions.
Psoriatic arthritis (PsA) is a long-term inflammatory arthritis that occurs in people affected by the autoimmune disease psoriasis. The classic feature of psoriatic arthritis is swelling of entire fingers and toes with a sausage-like appearance. This often happens in association with damage to the nails such as small depressions in the nail (pitting), thickening of the nails, and detachment of the nail from the nailbed. Skin damage consistent with psoriasis frequently occur before the onset of psoriatic arthritis but psoriatic arthritis can precede the rash in 15% of affected individuals. It is classified as a type of seronegative spondyloarthropathy.
Patient education is a planned interactive learning process designed to support and enable expert patients to manage their life with a disease and/or optimise their health and well-being.
Anti-citrullinated protein antibodies (ACPAs) are autoantibodies that are directed against peptides and proteins that are citrullinated. They are present in the majority of patients with rheumatoid arthritis. Clinically, cyclic citrullinated peptides (CCP) are frequently used to detect these antibodies in patient serum or plasma.
ACR score is a scale to measure change in rheumatoid arthritis symptoms. It is named after the American College of Rheumatology. The ACR score is more often used in clinical trials than in doctor patient-relationships, as it allows a common standard between researchers.
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.
The minimal important difference (MID) or minimal clinically important difference (MCID) is the smallest change in a treatment outcome that an individual patient would identify as important and which would indicate a change in the patient's management.
Systemic-onset juvenile idiopathic arthritis (sJIA), also known as Still disease, Still's disease, and systemic juvenile idiopathic arthritis, is a subtype of juvenile idiopathic arthritis (JIA) that is distinguished by arthritis, a characteristic erythematous skin rash, and remitting fever. Fever is a common symptom in patients with sJIA, characterized by sudden temperature rise above 39 °C and then a sudden drop. Over 80% of patients have a salmon-colored macular or maculopapular rash, which can be migratory and nonpruritic. Arthritis can develop weeks, months, or even years after onset and can affect various joints. SJIA is characterized by splenic and lymph node enlargements, with prominent symmetrical lymphadenopathy. Pericardial involvement is common, with 81% of children with active systemic symptoms having abnormal echocardiographic findings and 36% having an effusion or pericardial thickening. Around one-third of children with sJIA have occult macrophage activation syndrome (MAS), a potentially fatal illness causing T cells and macrophages to rapidly multiply and activate, resulting in a "cytokine storm."
International League of Associations of Rheumatology (ILAR) is an international body of the associations of Rheumatologists from around the world. It comprises partner organisations PANLAR, Pan American League of Associations for Rheumatology, EULAR, European League against Rheumatism, APLAR, Asia Pacific League of Associations of Rheumatology and AFLAR, African League of Associations for Rheumatology. ILAR has taken leadership in the development of global consensus on the diagnosis of rheumatological diseases especially juvenile idiopathic arthritis It published the ILAR Journal.
Rheumatoid disease of the spine is a morbid consequence of untreated longstanding severe cervical spinal rheumatoid arthritis (RA)–an inflammatory autoimmune disease that attacks the ligaments, joints, and bones of the neck. Although the anterior subluxation of the atlantoaxial joint is the most common manifestation of the disorder, subluxation can also occur with posterior or vertical movement, and subaxial joints can also be involved.
Gary S. Firestein is an American rheumatologist, professor, and founding director of the Altman Clinical and Translational Research Institute (ACTRI) at the University of California San Diego and Senior Associate Vice Chancellor for Health Sciences at University of California, San Diego.
Paul-Peter Tak is a Dutch immunologist and academic specialising in the fields of internal medicine, rheumatology and immunology. Tak has been the President & CEO of Candel Therapeutics since September 2020.
Nicola Dalbeth is a New Zealand academic rheumatologist whose research focuses on understanding the impact and mechanisms of gout. She supports clinical and laboratory research programmes and holds dual appointments as a full professor at the University of Auckland and as a consultant for the Auckland District Health Board.
A Core Outcome Set (COS) is a standardized set of domains and instruments that define the minimum outcomes to be measured and reported in all clinical trials related to a specific clinical area. It is developed through a rigorous consensus process involving diverse collaborators, including patient research partners, healthcare professionals, and researchers. The process has two key phases:
Peter Tugwell is a Canadian physician and Professor in the Department of Medicine and School of Epidemiology and Public Health at the University of Ottawa. He is known for promoting clinical epidemiology and championing for health equity worldwide. In 2013 he was named Officer of the Order of Canada for his efforts as "tireless contributor to global health".
Paul Emery is a British rheumatologist, researcher, and academic. Emery has been the Versus Arthritis Professor of Rheumatology at the University of Leeds from 1995 to 2017, Head of its Rheumatology Department from 1995 to 2008. He is Head of the Academic Unit of Musculoskeletal Disease and Lead Clinician of Rheumatology at the Leeds Teaching Hospital NHS Trust, and was the Director of the NIHR Leeds Biomedical Research Centre from 2009 to 2022. He is known for introducing early intervention in inflammatory arthritis. Emery played a critical role in bringing sensitive imaging (MRI) into rheumatology practice. In 2012, Emery was awarded the Carol Nachman Prize for Rheumatology, and as of 2024, he has published over 1660 peer-reviewed articles with over 160,000 citations. Emery was the most cited European/World Rheumatologist in 2010-2020, and was selected in the European Journal of Clinical Investigation's "list of highly influential biomedical researchers, 1996–2020."
Lynette (Lyn) March AM is an Australian rheumatologist and clinical epidemiologist. She is Liggins Professor of Rheumatology and Musculoskeletal Epidemiology in the Faculty of Medicine and Health at the University of Sydney, Australia.